Clinical Trial Update: A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II adaptive trial evaluating the pharmacokinetic and pharmacodynamic effects of the extended-release amphetamine HLD100 formulations (B, C, and E) in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• HLD100 (extended-release amphetamine)

Snippet

Sponsor: Ironshore Pharmaceuticals and Development, Inc | Conditions: Attention-Deficit Hyperactivity Disorder | Phase 1, Phase 2 | Status: COMPLETED